Catalyst

Slingshot members are tracking this event:

BioCryst (BCRX) Announces Plans to Expand Development of BCX7353 with ZENITH-1 Exploratory Trial in Acute Attacks in Patients with Hereditary Angioedema (HAE)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BCRX

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 12, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Bcx7353, Acute Attacks, Hereditary Angioedema, Hae, Zenith-1